Two groups of scientists have found that the same protein can have opposing effects on α-synuclein pathology. Microglia eliminate α-synuclein from neurons by “trogocytosis.” Silencing the glycoprotein ...

In the latest development on diagnostic methods for Alzheimer’s disease going mainstream, the U.S. Food and Drug Administration approved clinical use of Lantheus’ tau PET tracer florquinitau, aka ...

Anti-amyloid immunotherapies come with a risk of serious brain hemorrhage, which can be mitigated via monitoring for amyloid-related imaging abnormalities (ARIA) via MRI scans. Early signs of edema ...

The tau locus comes in two major genetic configurations, the H1 and H2 haplotypes. The latter carries a stretch of DNA, including the tau gene, that is flipped in orientation. As it turns out, a ...

The National Alzheimer’s Coordinating Center unites the collections of the neuropathology cores at 27 NIA-funded AD Research Centers into a single database. It contains records on 13,000 brains, 3,000 ...

Also the 24th Alzheimer's Disease and Related Disorders Annual convention of the Dementia Society of the Philippines ...

Tau, α-Synuclein Spread: Crazy Stuff—How Might It Work? Like Star Born of Supernova, Plaque Born of Exploded Neuron? Can Dousing PyroGlu-Aβ Treat Alzheimer’s Disease? Field Ramps Up "Mini" Mouse MRI ...

Past AlzForum Coverage: Human Amyloid Imaging 2013 Solanezumab Selected for Alzheimer’s A4 Prevention Trial HAI—Spotlight on Tau Tracers at Human Amyloid Imaging Meeting HAI—Amyloid Imaging in the ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug ...